内容摘要：Alexander said he felt he had "learned so much" over the last decade about the way he likes to work.

Alexander said he felt he had "learned so much" over the last decade about the way he likes to work.

"I think I lost my intensity a bit," said Swiatek."She played as strong as in the first set, but I didn't react to that well and just couldn't push back."

For the first time since 2011, fans had a home player to cheer in the women's semi-finals - and nobody could have guessed it would be Boisson.The 22-year-old's journey from an unknown player returning from serious injury to a Grand Slam semi-finalist competing with the world's best is extraordinary.Boisson was set to be a wildcard entry last year but had to pull out after tearing an anterior cruciate ligament just a week before the French Open began.

But 12 months on, she returned to make a remarkable run that will never be forgotten by French fans.Taking the scalps of third seed Jessica Pegula and sixth seed Mirra Andreeva put her into a first career semi-final on the biggest stage of all.

However, Gauff proved to be a step too far.

Despite having the backing of a raucous crowd on Court Philippe Chatrier, the energy provided was not enough to compensate for Boisson's lack of quality.Crucially, users of either drug can put weight back on once they stop treatment.

Wegovy is available on the NHS in England, Wales and Scotland.It must be prescribed by a weight management specialist, and access to these is restricted.

To qualify, adults must be obese (with a BMI of at least 35) and have at least one pre-existing weight-related health condition such as high blood pressure.People with cardiovascular disease who are classed as overweight, but not quite obese, can also be given the drug.